IGF2 and neoplasm: Consistent with the concept of a differential effect of IGFs in cancer, increased IGF-II bioavailability in the tumor microenvironment is also provided by reduced expression of its high affinity scavenger receptor SpI2-6 [12], formerly referred as IGF2 receptor, secondary to its loss of heterozygosity [51,52,53].